A simple LC-MS/MS method for determination of sitafloxacin in human urine

被引：2

作者：

Wang, Yuanyuan ^{[1
]}

Liu, Yang ^{[2
]}

Zhang, Hongwen ^{[1
]}

Wang, Yongqing ^{[1
]}

Liu, Yun ^{[1
]}

Wang, Libin ^{[1
]}

Ou, Ning ^{[1
]}

机构：

[1] Nanjing Med Univ, Affiliated Hosp 1, Dept Pharm, Nanjing 210029, Jiangsu, Peoples R China

[2] Nanjing Med Univ, Sch Pharm, Nanjing 210029, Jiangsu, Peoples R China

来源：

JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES | 2014年 / 967卷

关键词：

Sitafloxacin; LC-MS/MS; Urine; Urine recovery study; RESPIRATORY-TRACT INFECTIONS; PHARMACOKINETICS; FLUOROQUINOLONE;

D O I：

10.1016/j.jchromb.2014.07.015

中图分类号：

Q5 [生物化学];

学科分类号：

071010 ; 081704 ;

摘要：

Sitafloxacin is a new fluoroquinolone antimicrobial agent with high activity. In this article, we reported a simple, rapid and specific LC-MS/MS method for accurate determination of sitafloxacin concentrations in human urine from healthy volunteers in detail. A two-step dilution method for the analysis of sitafloxacin in human urine using LC coupled to positive MS/MS has been developed and validated according to US FDA guidelines and Chinese State Food and Drug Administration (CFDA) guidelines for the validation of bioanalytical methods. The method uses 50 mu L of urine and covers a working range from 0.025 to 20 mu g/mL with a LLOQ of 0.025 mu g/mL. This new LC-MS/MS assay is sensitive and specific. (C) 2014 Elsevier B.V. All rights reserved.

引用

页码：219 / 224

页数：6

共 8 条

[1]

[Anonymous], 2001, Guidance for Industry Bioanalytical Method Validation

[2] Determination of sitafloxacin in human plasma by liquid chromatography-tandem mass spectrometry method: Application to a pharmacokinetic study [J].

Huang, Kai ;

Yang, Jie ;

Zhang, Jing ;

Ding, Ying ;

Chen, Lan ;

Xu, Wen-Yan ;

Xu, Xue-Jiao ;

Duan, Ru ;

He, Qing .

JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2014, 957 :36-40

[3] Clinical dose findings of sitafloxacin treatment: pharmacokinetic-pharmacodynamic analysis of two clinical trial results for community-acquired respiratory tract infections [J].

Kohno, Shigeru ;

Niki, Yoshihito ;

Kadota, Jun-ichi ;

Yanagihara, Katsunori ;

Kaku, Mitsuo ;

Watanabe, Akira ;

Aoki, Nobuki ;

Hori, Seiji ;

Fujita, Jiro ;

Tanigawara, Yusuke .

JOURNAL OF INFECTION AND CHEMOTHERAPY, 2013, 19 (03) :486-494

[4] PHARMACOKINETICS AND TOLERANCE OF DU-6859A, A NEW FLUOROQUINOLONE, AFTER SINGLE AND MULTIPLE ORAL DOSES IN HEALTHY-VOLUNTEERS [J].

NAKASHIMA, M ;

UEMATSU, T ;

KOSUGE, K ;

UMEMURA, K ;

HAKUSUI, H ;

TANAKA, M .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1995, 39 (01) :170-174

[5] Pharmacokinetics and absolute bioavailability of sitafloxacin, a new fluoroquinolone antibiotic, in healthy male and female Caucasian subjects [J].

O'Grady, J ;

Briggs, A ;

Atarashi, S ;

Kobayashi, H ;

Smith, RL ;

Ward, J ;

Ward, C ;

Milatovic, D .

XENOBIOTICA, 2001, 31 (11) :811-822

[6]

Tachibana M, 2004, ARZNEIMITTEL-FORSCH, V54, P898

[7] Population pharmacokinetics and pharmacodynamics of sitafloxacin in patients with community-acquired respiratory tract infections [J].

Tanigawara, Yusuke ;

Kaku, Mitsuo ;

Totsuka, Kyoichi ;

Tsuge, Hiroyuki ;

Saito, Atsushi .

JOURNAL OF INFECTION AND CHEMOTHERAPY, 2013, 19 (05) :858-866

[8] Dialyzability and Pharmacokinetics of Sitafloxacin Following Multiple Oral Dosing in Infected Hemodialysis Patients [J].

Tsuruoka, Shuichi ;

Yokota, Noritsugu ;

Hayasaka, Tokie ;

Saito, Tetsuo ;

Yamagata, Kunihiro .

THERAPEUTIC APHERESIS AND DIALYSIS, 2013, 17 (03) :319-324

← 1 →